Sources: 44NIH Clinical Center, 4ClinicalTrials, 32LifeMap Discovery®, 65UMLS, 43NDF-RT, 13DrugBank, 26HMDB, 9DGIdb, 53PharmGKB, 30IUPHAR, 47Novoseek, 1BitterDBSee all MalaCards sources |
Drugs for Acute Liver Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 327)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Entecavir | approved, investigational | Phase 4, Phase 2 | 170 | 142217-69-4 | 153941 | 142217-69-4 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1) 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one 209216-23-9 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl] 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate AB1004838 AC-1593 AC1L4BEC BMS-200475 Baraclude Baraclude (TN) CHEBI:473990 CHEBI:59902 CHEMBL713 | CID153941 D04008 D07896 DB00442 ETV Entecavir Entecavir (INN) Entecavir (USAN) Entecavir hydrate Entecavir hydrate (JAN) Entecavirum FT-0083013 MolPort-005-942-963 S2128_Selleck SBB066120 SQ-34676 TL8000933 ZINC03802690 entecavir monohydrate |
| | 2 | | Miconazole | approved, investigational | Phase 4, Phase 3, Phase 2 | 3026 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv Desenex DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Makesense Micantin (nitrate) Micatin | Miconasil Nitrate Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Oravig Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 Rash Relief Antifungal SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole |
| | 3 | | Alprostadil | approved, investigational | Phase 4, Phase 2 | 63 | 745-65-3 | 149351, 5280723 | (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid (-)-Prostaglandin E1 (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate (13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate (13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid (13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate (13e)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoate (13e)-(15S)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid 11,15-Dihydroxy-9-oxoprost-13-en-1-oate 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid 11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0) 119314-69-1 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate 3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid 745-65-3 82474_FLUKA A0593_SIAL AB00514004 AC-6095 AC1NQXHQ Alista Alprostadil Alprostadil (JP15/USP/INN) Alprostadil Alfadex Alprostadil Prostoglandin E1 Alprostadil(usan) Alprostadilum Alprox-TD BIDD:GT0747 BML1-F06 BPBio1_001293 BRD-K52459643-001-06-0 BSPBio_001175 BSPBio_001488 Befar Befar (TN) C04741 CHEBI:15544 CHEMBL495 CID5280723 CPD000112594 Caverject Caverject Impulse D00180 DB00770 EDEX Edex | FemLife Femprox HEI-507 HMS1361K10 HMS1571K17 HMS1791K10 HMS1989K10 HMS2052L11 HMS2090L08 IDI1_033958 L-Prostaglandin E1 LMFA03010134 MLS000758964 MLS001424250 MR 256 MR-256 MUSE MolPort-003-939-183 Muse NCGC00025234-02 NCGC00025234-03 NCGC00025234-04 NCGC00025234-05 P5515_SIAL P5515_SIGMA P7527_SIGMA P8908_SIGMA PGE-1 PGE1 PGE1 Oligomer PGE1 α-CD PGE₁ Prestwick2_001018 Prestwick3_001018 Prink Prink (TN) Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer Prostaglandin E1 Prostaglandin e1 Prostavasin Prostin VR Prostin VR PEDIATRIC Prostin VR Pediatric Prostin VR pediatric (TN) Prostin vr RayVa SAM001246840 SAM001246845 SAM001247093 SMP2_000271 SMR000112594 ST50826271 Sugiran Topiglan U-10136 Viridal Vitaros alprostadil l-Prostaglandin E1 | |
| | 4 | | Prednisolone | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1082 | 50-24-8 | 5755 | (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione .DELTA.1-Cortisol .DELTA.1-Dehydrocortisol .DELTA.1-Dehydrohydrocortisone .DELTA.1-Hydrocortisone .delta.-Cortef .delta.-Stab 1,2-Dehydrohydrocortisone 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol 1-Dehydrocortisol 1-Dehydrohydrocortisone 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene 46656_FLUKA 46656_RIEDEL 50-24-8 58201-11-9 8056-11-9 AC-1773 AC1L1L2E Ak-Pred Ak-Tate Alphadrol Articulose-50 BPBio1_000164 BRD-K98039984-001-03-0 BRN 1354103 BSPBio_000148 Bio-0666 Bubbli-Pred C07369 CCRIS 980 CHEBI:8378 CHEMBL131 CID5755 CO-Hydeltra CPD000718761 Co-Hydeltra Codelcortone Cordrol Cortalone Cotogesic Cotolone D00472 D011239 DB00860 Decaprednil Decortin H Delcortol Delta F Delta(1)-dehydrohydrocortisone Delta-Cortef Delta-Cortef (TN) Delta-Ef-Cortelan Delta-Stab Delta-stab Deltacortenol Deltacortril Deltacortril Enteric Deltahydrocortisone Deltasolone Deltisilone Depo-Medrol Derpo PD Derpo Pd Dexa-Cortidelt Hostacortin H Dexa-Cortidelt hostacortin H Di Adreson F Di-Adreson F Di-Adreson-F Di-adreson F DiAdresonF Dicortol Donisolone Dydeltrone EINECS 200-021-7 Eazolin D Econopred Econopred Plus Erbacort Erbasona Estilsona Fernisolone Fernisolone P Fernisolone-P Flamasone Flo-pred HMS1568H10 HMS2090J05 HSDB 3385 Hostacortin H Hydeltra Hydeltra-Tba Hydeltrasol Hydeltrone Hydrodeltalone Hydrodeltisone Hydroretrocortin Hydroretrocortine I-Pred Inflamase Forte Inflamase Mild K 1557 Key-Pred Klismacort LMST02030179 LS-7669 Lentosone Lite Pred M-Predrol MLS001304083 | MLS002154250 MLS002207037 Medrol Medrol Acetate Metacortandralone Methylprednisolone Acetate Meti-Derm Meticortelone Metreton Millipred MolPort-002-507-147 NCGC00179649-01 NSC 9120 NSC9120 NSC9900 Neo-Delta-Cortef Nisolone Nor-Pred T.B.A. Ocu-Pred Ocu-Pred Forte Omnipred Ophtho-Tate Orapred P0152_SIGMA P0637 P6004_SIGMA PRDL PRED-G Panafcortelone Paracortol Paracotol Pediapred Poly-Pred Precortalon Precortancyl Precortilon Precortisyl Pred Forte Pred Mild Predair Predair A Predair Forte Predalone 50 Predalone T.B.A. Predate Predate Tba Predate-50 Predcor-25 Predcor-50 Predcor-Tba Predisolone Sodium Phosphate Predne-Dome Prednelan Predni-Dome Prednicen Predniliderm Predniretard Prednis Prednisolona Prednisolona [INN-Spanish] Prednisolone Prednisolone (JP15/USP/INN) Prednisolone (anhydrous) Prednisolone Acetate Prednisolone Sodium Phosphate Prednisolone Tebutate Prednisolone [INN:BAN:JAN] Prednisolonum Prednisolonum [INN-Latin] Predonin Predonine Prelone Prenolone Prestwick0_000274 Prestwick1_000274 Prestwick2_000274 Prestwick3_000274 Prestwick_404 Rolisone S1737_Selleck SAM002264639 SMR000718761 SPBio_002367 Scherisolon Solone Steran Sterane Sterolone Supercortisol UNII-9PHQ9Y1OLM Ulacort Ultra Pred Ultracorten H Ultracortene H Ultracortene-H Ultracortene-Hydrogen Ultracortene-hydrogen ZINC03833821 component of Ataraxoid component of K-Predne-Dome delta(1)-Cortisol delta(1)-Dehydrocortisol delta(1)-Dehydrohydrocortisone delta(1)-Hydrocortisone delta(sup 1)-Cortisol delta(sup 1)-Dehydrocortisol delta(sup 1)-Dehydrohydrocortisone delta(sup 1)-Hydrocortisone delta-dehydrocortisol delta-dehydrohydrocortisone delta-hydrocortisone prednisolone | |
| | 5 | | Methylprednisolone | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 1082 | 83-43-2 | 6741 | (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one (6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione .DELTA.1-6.alpha.-Methylhydrocortisone 1-Dehydro-6alpha-methylhydrocortisone 1-dehydro-6alpha-Methylhydrocortisone 1-dehydro-6α-methylhydrocortisone 11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione 11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 121673-01-6 4-08-00-03498 (Beilstein Handbook Reference) 46436_FLUKA 46436_RIEDEL 570-35-4 6 Methylprednisolone 6-Methylprednisolone 6-alpha-Methylprednisolone 6.alpha.-Methylprednisolone 6923-42-8 6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 6alpha-Methylprednisolone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione 83-43-2 A-methapred AC1L1N7A Artisone-Wyeth Artisone-wyeth BPBio1_000174 BRD-K35240538-001-03-1 BRN 2340300 BSPBio_000158 Besonia Bio-0658 CHEBI:6888 CHEMBL650 CID6741 CPD000058330 D00407 D008775 DB00959 Depo-Medrol (acetate) Depo-medrol Dopomedrol EINECS 201-476-4 Esametone Firmacort HMS1568H20 HMS2090B13 HSDB 3127 LMST02030178 LS-118498 Lemod M0639_SIGMA M1665 MEPRDL MLS000028541 MLS001148159 MLS002207191 Medesone Medixon Medlone 21 | Medrate Medrol Medrol (TN) Medrol Adt Pak Medrol Dosepak Medrol adt pak Medrol dosepak Medrol, Solu-Medrol, Medrone, Methylprednisolone Medrone Mesopren Metastab Methyleneprednisolone Methylprednisolon Methylprednisolone Methylprednisolone (JP15/USP/INN) Methylprednisolone [USAN:INN:BAN:JAN] Methylprednisolone, 6-alpha Methylprednisolonum Methylprednisolonum [INN-Latin] Metilbetasone Metilprednisolona Metilprednisolona [INN-Spanish] Metilprednisolone Metilprednisolone [DCIT] Metilprednisolone [Dcit] Metipred Metrisone Metrocort Metysolon Moderin MolPort-002-528-554 NCGC00022735-03 NCI60_001657 NSC-19987 NSC19987 Nirypan Noretona Predni N Tablinen Prednol- L Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI) Prestwick0_000279 Prestwick1_000279 Prestwick2_000279 Prestwick3_000279 Prestwick_622 Promacortine Reactenol S1733_Selleck SAM002589984 SMR000058330 SPBio_002377 Sieropresol Solomet Solu-medrol Summicort Suprametil U 7532 UNII-X4W7ZR7023 Urbason Urbasone Wyacort ZINC03875560 delta(1)-6alpha-Methylhydrocortisone delta(sup 1)-6-alpha-Methylhydrocortisone methylprednisolone methylprenisolone | |
| | 6 | | Lactulose | approved | Phase 4, Phase 3, Phase 2 | 91 | 4618-18-2 | 11333 | (2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol 4-O-b-D-Galactopyranosyl-D-Fructofuranose 4-O-b-D-Galactopyranosyl-D-fructose 4-O-beta-D-Galactopyranosyl-D-Fructofuranose 4-O-beta-D-Galactopyranosyl-D-fructofuranose 4-O-beta-D-Galactopyranosyl-D-fructose 4-O-beta-delta-Galactopyranosyl-delta-Fructofuranose 4-O-beta-delta-Galactopyranosyl-delta-fructose Bifiteral Cephulac | Constulose D-Lactulose Enulose Generlac Kristalose Lactulosa Lactulose Lactulosum delta-Lactulose lactulosa lactulosum | |
| | 7 | | Rifaximin | approved, investigational | Phase 4, Phase 2 | 94 | 80621-81-4 | 6436173 | (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin 80621-81-4 88747-56-2 AC-19112 BRN 3584528 Bio-0556 C43H51N3O11 CHEMBL1617 D02554 DB01220 Fatroximin Flonorm L 105 L 105 (Ansamacrolide antibiotic) L 105SV LS-178059 LS-64147 Lormyx Lumenax MLS000759430 Normix RedActiv Rifacol | Rifamixin Rifamycin L 105 Rifamycin L 105SV Rifaxidin Rifaximin Rifaximin (USAN/INN) Rifaximin [USAN:INN] Rifaximina Rifaximina [Spanish] Rifaximine Rifaximine [French] Rifaximinum Rifaximinum [Latin] Rifaximinun Rifaxin Ritacol S1790_Selleck SMR000466324 Spiraxin UNII-L36O5T016N Xifaxan Xifaxan, Rifacol, Fatroximin, Rifaximin Xifaxsan Xifaxsan (TN) Zaxine alpha-0817185 | |
| | 8 | | Prednisone | approved | Phase 4, Phase 3, Phase 2 | 1267 | 53-03-2 | 5865 | (1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione (8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione .delta. E .delta.(sup1)-Cortisone .delta.-Cortelan .delta.-Cortisone .delta.-Cortone .delta.-E .delta.1-Cortisone .delta.1-Dehydrocortisone .delta.sone 1,2-Dehydrocortisone 1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione 1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione 1-Cortisone 1-Dehydrocortisone 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione 53-03-2 68-59-7 81552_FLUKA AC-11112 AC1L1LB2 AC1Q29EZ ACon0_000082 ACon1_000297 AI3-52939 Adasone Ancortone Apo-Prednisone Apo-prednisone BPBio1_000323 BRD-K85883481-001-04-2 BSPBio_000293 Betapar Bicortone Bio-0649 C07370 C21H26O5 CCRIS 2646 CHEBI:8382 CHEMBL635 CID5865 CPD001227202 Cartancyl Colisone Cortan Cortancyl Cortidelt Cotone DB00635 Dacorten Dacortin Decortancyl Decortin Decortisyl Dehydrocortisone Dekortin Delcortin Dellacort Dellacort A Delta Cortelan Delta E Delta E. Delta-Cortelan Delta-Dome Delta-cortelan Delta-cortisone Delta-cortone Delta-dome Deltacortene Deltacortisone Deltacortone Deltasone Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone Deltison Deltisona Deltisone Deltra Di-Adreson Diadreson EINECS 200-160-3 Econosone Encorton Encortone Enkortolon Enkorton Fernisone Fiasone HMS1568O15 HMS2090J13 HSDB 3168 Hostacortin In-Sone Incocortyl Juvason | Kortancyl LMST02030180 LS-1325 Liquid Pred Lisacort Lodotra MEGxm0_000443 MLS001061265 MLS001304073 MLS001335907 MLS001335908 MLS002154191 MLS002207083 Me-Korti Metacortandracin Meticorten Meticorten (Veterinary) Metrevet (Veterinary) MolPort-001-740-041 NCGC00090766-01 NCGC00090766-02 NCGC00090766-03 NCI-C04897 NCI60_000008 NSC 10023 NSC10023 Nisona Nizon Novoprednisone Nurison Orasone Origen Prednisone P1276 P6254_SIGMA PRD Panafcort Panasol Paracort Parmenison Pehacort Perrigo Prednisone Precort Predeltin Prednicen-M Prednicorm Prednicort Prednicot Prednidib Prednilonga Prednison Prednisona Prednisona [INN-Spanish] Prednisone Prednisone Intensol Prednisone [INN:BAN] Prednisonum Prednisonum [INN-Latin] Prednitone Prednizon Prednovister Presone Prestwick0_000077 Prestwick1_000077 Prestwick2_000077 Prestwick3_000077 Prestwick_405 Pronison Pronisone Rayos Rectodelt Retrocortine S1622_Selleck SAM002264641 SK-Prednisone SMR000718760 SMR001227202 SPBio_002214 Servisone Sone Sterapred Supercortil U 6020 UNII-VB0R961HZT Ultracorten Ultracortene WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ Winpred Wojtab ZINC03875357 Zenadrid Zenadrid (veterinary) Zenadrid [veterinary] delta cortelan delta(sup 1)-Cortisone delta(sup 1)-Dehydrocortisone delta-1-Cortisone delta-1-Dehydrocortisone delta-Cortisone delta-Cortone | |
| | 9 | | Tacrolimus | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 1023 | 104987-11-3 | 445643, 439492, 445647 | (-)-FK 506 (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone 104987-11-3 109581-93-3 (Hydrate) 15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone, 3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone 8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN 8-DEETHYL-8-[but-3-enyl]-ascomycin AC-1182 AC1L1K7H AC1L97GB AC1L9IBU AKOS005145901 Advagraf Ambap104987-11-3 Ambap5429 BCBcMAP01_000194 BRD-K35452788-001-02-1 BSPBio-001279 BSPBio_001279 Bio-0921 Bio2_000470 Bio2_000950 C01375 C44H69NO10 CCRIS 7124 CHEBI:100924 CHEBI:61049 CHEMBL1200738 CID11158639 CID11556866 CID439492 CID445643 CID5372 CID5472317 CID6426916 CID6436007 CID6473866 CID6536850 CID6610362 CID6912836 CID9832283 CID9853905 CID9918805 CID9940643 CID9963169 CPD-10016 CPD000466356 D08556 DB00864 DivK1c_001040 FK 506 FK-506 FK5 FK506 FR 900506 FR-900506 FR900506 | FT-0082660 Fk-506 Fujimycin Graceptor HMS1362O21 HMS1792O21 HMS1990O21 HMS2051C18 HMS2093M19 HMS503O21 Hecoria IDI1_001040 IDI1_002225 K506 KBio1_001040 KBio2_000619 KBio2_003187 KBio2_005755 KBio3_001097 KBio3_001098 KBioGR_000619 KBioSS_000619 L 679934 L-679934 LCP-Tacro LMPK04000003 LS-64247 MLS000759471 MLS001424054 Modigraf MolPort-003-666-518 NCGC00163470-01 NCGC00163470-02 NCGC00163470-03 NCGC00163470-04 NCGC00179232-01 NChemBio.2007.16-comp1 NINDS_001040 NSC717865 Prograf Prograf (TN) Protopic Protopy S5003_Selleck SAM001246677 SMR000466356 Tacarolimus Tacrolimus Tacrolimus (INN) Tacrolimus (Prograf?) Tacrolimus (anhydrous) Tacrolimus Hydrate Tacrolimus anhydrous Tacrolimus hydrate Tsukubaenolide UNII-Y5L2157C4J nchembio.2007.23-comp2 tacrolimus tacrolimus hydrate | |
| | 10 | | Mycophenolate mofetil | approved, investigational | Phase 4, Phase 3, Phase 2, Phase 1 | 898 | 128794-94-5 | 5281078 | 115007-34-6 128794-94-5 140401-05-4 2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E) AC-1562 AC1NQXZW AC1Q6O6X AR-1J6939 BB_NC-2566 C07908 C23H31NO7 CHEMBL1456 CID5281078 CellCept CellCept, RS 61443, TM-MMF, Mycophenolate mofetil Cellcept Cellcept (TN) D00752 DB00688 HMS2090A03 | HSDB 7436 I01-0898 I06-1947 LS-172272 LS-75572 ME-MPA MMF MMF CellCept(TM) MolPort-000-883-800 Munoloc Mycophenolate Mofetil Mycophenolate mofetil (JAN/USAN) Mycophenolic acid morpholinoethyl ester Mycophenylate mofetil NCGC00159459-02 NCGC00159459-03 NSC724229 R-99 RS 61443 RS-61443 RS-61443-190 S1501_Selleck TL8000648 TM-MMF UNII-9242ECW6R0 ZINC21297660 mycophenolate mofetil |
| | 11 | | Acetylcysteine | approved | Phase 4, Phase 3, Phase 2 | 293 | 616-91-1 | 12035 | (2R)-2-acetylamino-3-Sulfanylpropanoic acid (R)-2-acetylamino-3-Mercaptopropanoic acid (R)-Mercapturic acid 2-Acetylamino-3-mercapto-propionate 2-Acetylamino-3-mercapto-propionic acid ACC Acetadote Acetilcisteina Acetylcysteine Acetylcysteinum Fluimicil Infantil Fluimucetin Fluimucil Flumucetin | Fluprowit L-Acetylcysteine L-alpha-acetamido-beta-Mercaptopropionic acid Lysox Mercapturic acid Mucolysin Mucomyst N-ACETYL-L-cysteine N-Acety-L-Cysteine N-Acetyl-3-mercaptoalanine N-Acetyl-L-(+)-cysteine N-Acetylcysteine N-acetylcysteine NAC Parvolex Sodium 2-acetamido-3-mercaptopropionate |
| | 12 | | Daclizumab | approved, investigational | Phase 4, Phase 3 | 96 | 152923-56-3 | | Anti-IL-2 Humanized antiCD25 | Ig gamma-1 chain C region Simulect chimeric mouse-human antiCD25 | |
| | 13 | | Heparin | approved, investigational | Phase 4, Phase 1 | 719 | 9005-49-6 | 772, 46507594 | 101921-26-0 102-94-3 102785-31-9 104521-37-1 11078-24-3 11129-39-8 12656-11-0 2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose 37324-73-5 6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid 9041-08-1 9045-22-1 9075-96-1 913079-23-9 91449-79-5 AC1L19ZN AC1L1ROY ALFA 87-120 ALFA 87-163 ALFA 87-198 ALFA 87-81 ALFA 88-247 AR-1E4539 Allocinnamic acid Ardeparin Ardeparin sodium Arteven Bemiparin Bemiparin sodium CID772 CID8784 CY 216 Calciparine Certoparin Clexane Clivarin Clivarine Cy 222 D006495 D017984 DB00407 DB01225 Dalteparin Dalteparin sodium Depo-Heparin EINECS 232-681-7 EMT 966 EMT 967 EMT-966 EMT-967 EMT966 EMT967 Enoxaparin Enoxaparin sodium Enoxaparine Eparina Eparina [DCIT] FR 860 Fluxum Fragmin A Fragmin B Fragmin IV Fraxiparin H 2149 HSDB 3094 Hed-heparin Hep Flush Kit in plastic container Hep-Lock Hep-Lock U/P Hep-lock Heparin Heparin CY 216 Heparin Lock Flush Heparin Lock Flush in plastic container Heparin Lock Flush preservative free Heparin Lock Flush preservative free in plastic container Heparin Sodium Heparin natrium Heparin sodium Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container Heparin sodium 1,000 units in dextrose 5% in plastic container Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container Heparin sodium 10,000 units in dextrose 5% Heparin sodium 10,000 units in dextrose 5% in plastic container Heparin sodium 10,000 units in sodium chloride 0.45% Heparin sodium 10,000 units in sodium chloride 0.9% Heparin sodium 12,500 units in dextrose 5% Heparin sodium 12,500 units in dextrose 5% in plastic container Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container Heparin sodium 12,500 units in sodium chloride 0.9% Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container Heparin sodium 2,000 units in dextrose 5% in plastic container Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container Heparin sodium 20,000 units and dextrose 5% in plastic container Heparin sodium 20,000 units in dextrose 5% in plastic container Heparin sodium 25,000 units and dextrose 5% in plastic container | Heparin sodium 25,000 units in dextrose 5% Heparin sodium 25,000 units in dextrose 5% in plastic container Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container Heparin sodium 25,000 units in sodium chloride 0.9% Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container Heparin sodium 5,000 units in dextrose 5% in plastic container Heparin sodium 5,000 units in sodium chloride 0.45% Heparin sodium 5,000 units in sodium chloride 0.9% Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container Heparin sodium in plastic container Heparin sodium preservative Free Heparin sulfate Heparin sulphate Heparin, Low Molecular Weight Heparin, Low-Molecular-Weight Heparin, sodium salt Heparina Heparina [INN-Spanish] Heparinate Heparine Heparine [INN-French] Heparinic acid Heparinsodiumsalt Heparinum Heparinum [INN-Latin] Heparinum natricum Hepathrom Hepflush-10 Inno-Hep Innohep Isocinnamic acid KB 101 Kabi 2165 LHN 1 LMWH Lioton 1000 Lipo-hepin Liquaemin Liquaemin Lock Flush Liquaemin Sodium Liquaemin sodium preservative free Liquemin Logiparin Lovenox Lovenox HP Low Molecular Weight Heparin Low molecular weight heparin Low molecular weight heparin sodium Low-Molecular-Weight Heparin Minolteparin sodium MolPort-003-760-257 Multiparin NSC174025 Nadroparin Nadroparine Novoheparin OP 386 OP 622 Octaparin PK 10,169 PK-10,169 PK-10169 PK10,169 PK10169 Pabyrin Panheprin Parnaparin Parnaparin sodium Parvoparin Pularin Reviparin Reviparin sodium Ro 11 Sandoparin Sodium acid heparin Sodium heparin Sodium heparinate Subeparin Sublingula Thromboliquine Tinzaparin Tinzaparin sodium Triofiban UNII-12M44VTJ7B UNII-3S182ET3UA UNII-E47C0NF7LV UNII-T2410KM04A UNII-ZZ45AB24CA Vetren Vitrum AB WY 90493RD alpha-Heparin cis-.beta.-Carboxystyrene cis-Cinnamic acid enoxaparin heparin | |
| | 14 | | Mycophenolic acid | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 898 | 24280-93-1 | 446541 | (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid Acide mycophenolique Acido micofenolico Acidum mycophenolicum Melbex | Micofenolico acido Mycophenoic acid Mycophenolate Mycophenolic Acid Mycophenolsaeure Myfortic | |
| | 15 | | Tenofovir | approved, investigational | Phase 4 | 666 | 147127-20-6 | 464205 | (R)-9-(2-Phosphonomethoxypropyl)adenine (R)-9-(2-Phosphonylmethoxypropyl)adenine (R)-PMPA 147127-20-6 206184-49-8 AC-760 AC1LA9BO Anh. tenofovir Anhydrous tenofovir Apropovir CHEBI:45809 CHEMBL483 CID464205 D,L-Tenofovir DB00300 GNA & Tenofovir GS 1275 GS 1278 GS1278 HHA & Tenofovir | KS-5021 MolPort-003-850-411 NCGC00167535-01 PMPA PMPA-(R) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA) Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI) Phosphonic acid, [[2-(6-amino-9H-purin-9 S1401_Selleck TDF TFV Tenefovir Tenofovir Tenofovir (anh.) Tenofovir Disoproxil Fumarate Tenofovir disoproxil Tenofovir disoproxil fumarate UNII-99YXE507IL Viread Viread, Tenofovir [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid |
| | 16 | | Lamivudine | approved, investigational | Phase 4 | 594 | 134678-17-4 | 60825 | (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (+/-)-3TC (+/-)-BCH-189 (+/-)-SddC (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (-)-2'-Deoxy-3'-thiacytidine (-)-BCH 189 (-)-BCH-189 (-)-SddC (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine (-)NGPB-21 (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To 134678-17-4 2',3' Dideoxy 3' thiacytidine 2',3'-Dideoxy-3'-thiacytidine 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis) 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA) 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA) 3'-Thia-2',3'-dideoxycytidine 3-TC 3TC 3TC & GNA 3TC & SST 3TC (AIDS INITIATIVE) (AIDS INITIATIVE) 3TC and NV-01 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one 480434-79-5 AC-1416 AC1L1TZZ AC1Q6C34 BCH 189 BCH-189 BCH-790 BCH189 BIDD:GT0033 Bio-0652 C07065 C8H11N3O3S CCRIS 9274 CHEBI:133986 CHEMBL141 CID60825 CPD000466319 D00353 D019259 DB00709 | DRG-0126 DTHC Epivir Epivir (TN) Epivir HBV Epivir(TM) Epivir-HBV Epzicom FT-0082667 GG-714 GR 109714 X GR 109714X GR-109714X GR109714X HHA & 3TC HHA & Lamivudine HMS2051D21 HSDB 7155 Hepitec Heptivir Heptodin Heptovir L0217 LMV LS-2107 Lamivir Lamivudin Lamivudina Lamivudine Lamivudine & GNA Lamivudine (JAN/USP/INN) Lamivudine [USAN:BAN:INN] Lamivudine [USAN:INN:BAN] Lamivudine [Usan:Ban:Inn] Lamivudine, (2S-cis)-Isomer Lamivudinum MLS000759424 MLS001424097 MolPort-002-507-347 NCGC00159341-03 NCGC00159341-04 NSC620753 S1706_Selleck SAM001246582 SAM002589994 SMR000466319 STK801940 UNII-2T8Q726O95 ZINC00012346 Zeffix Zefix beta-L-2',3'-Dideoxy-3'-thiacytidine beta-L-3'-Thia-2',3'-dideoxycytidine lamivudine | |
| | 17 | | Magnesium Sulfate | approved | Phase 4 | 154 | 7487-88-9 | 24083 | (C10-C16) Alkylalcohol sulfuric acid, magnesium salt 00627_FLUKA 10028-26-9 10034-99-8 (heptahydrate) 13143_RIEDEL 13143_SIAL 139939-75-6 18939-43-0 203726_ALDRICH 208094_SIAL 34276_FLUKA 34276_RIEDEL 38146_FLUKA 38146_RIEDEL 63126_FLUKA 63136_FLUKA 63136_SIAL 63139_FLUKA 63139_SIAL 68081-97-0 7487-88-9 AC1L2N76 AC1LAX36 AC1Q1U66 AI3-02029 Bitter salt C10-C16 Alkyl alcohol sulfuric acid magnesium salt CCRIS 8411 CHEBI:32599 CID24083 CPD0-2390 Caswell No. 534 D008278 DB00653 EINECS 231-298-2 EINECS 233-073-4 EINECS 242-691-3 EINECS 268-365-0 EPA Pesticide Chemical Code 050503 Epsom Sal Epsom Salt Epsom Salt Magnesium Sulfate Epsom Salt Soaking Solution Epsom salt HSDB 664 Hair salt Health Smart Natural Epsom Salt Heptahydrate Magnesium Sulfate Humco Epson Salt Kieserite [as monohydrate] LS-88605 M2643_SIGMA M3409_SIGMA | M7506_SIAL M8150_SIGMA MAGNESIUM SULFATE Magnesium Sulfate Magnesium Sulfate In Plastic Container Magnesium Sulfate, Heptahydrate Magnesium Sulphate Hydrate Magnesium bisulfate Magnesium hydrogensulphate Magnesium sulfate Magnesium sulfate (1:1) Magnesium sulfate anhydrous Magnesium sulfate dried Magnesium sulfate heptahydrate Magnesium sulfate hexahydrate Magnesium sulfate in dextrose 5% in plastic container Magnesium sulfate solution Magnesium sulphate Magnesium sulphate anhydrous Magnesium sulphate dried Magnesium sulphate heptahydrate Magnesium(II) sulfate Magnesium(ii) sulfate Magnesiumsulfat MgSO4 MolPort-003-925-000 Morton Natural Epsom Salt NSC 146179 Natural Epsom Salt OT-S OT-S (drying agent) Pepsom Flying P Epsom Salt Pepsom Salt Peppermint Royal Epsom Salt SDA 15-062-07 Sal Angalis Sal De sedlitz Sal amarum Sal anglicum Sal catharticum Sal seidlitense Salts of england Sel d'angleterre Sulfate, Magnesium Sulfuric acid magnesium salt Sulfuric acid magnesium salt (1:1) Sulfuric acid magnesium salt (VAN) Sulfuric acid, C10-16 alkyl ester, magnesium salt Sulfuric acid, magnesium salt Sulfuric acid, magnesium salt (1:1) Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts Tomix OT UNII-DE08037SAB UNII-ML30MJ2U7I magnesium(2+) ion sulfate |
| | 18 | | Caspofungin | approved | Phase 4 | 61 | 179463-17-3, 162808-62-0 | 468682, 2826718 | (4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide (4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide (4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide 1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 162808-62-0 AC1L45LR AC1LAHR5 AC1MCVUN AR-1K4318 CASPO CHEBI:474180 CHEMBL374999 CHEMBL499808 CID151068 CID2826718 CID468682 Cancidas Cancidas (TM) | Cancidas (TN) Capsofungin Caspofungin Caspofungin (INN) Caspofungin [INN] Caspofungin acetate D07626 DB00520 HSDB 7476 L-743,872 LS-186994 LS-187303 LS-187635 M991 MK-0991 N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI) UNII-F0XDI6ZL63 [1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide nchembio.184-comp7 |
| | 19 | | Citalopram | approved | Phase 4 | 494 | 59729-33-8 | 2771 | 1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile 1,3-dihydro[3,4]benzofuran-5-carbonitrile 1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile 59729-33-8 AB00513896 AC-12214 AC1L1EFH AE-641/00603021 Akarin BPBio1_000929 BRD-A47598013-004-02-0 BSPBio_000843 Bonitrile C07572 C20H21FN2O CHEBI:3723 CHEMBL549 CID2771 CPD000465669 Celapram Celexa Celius Ciazil Cilift Cipram Cipramil Ciprapine Citabax Citadur Citadur (TN) Citalec Citalopram Citalopram (USP/INN) Citalopram Hydrobromide Citalopram [Celexa] Citalopram [INN:BAN] Citalopram hydrobromide Citalopramum Citalopramum [INN-Latin] | Citol Citopam Citox Citrol Cytalopram D07704 DB00215 Dalsan EINECS 261-891-1 Elopram HMS2090O09 HMS2093A14 Humorup I01-0382 InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3 L001223 LS-84327 Lopac0_000258 Lu 10-171 Lu-10-171 MolPort-003-666-794 NCGC00015267-07 NCGC00025160-02 Nitalapram Oropram Perrigo Citalopram Pramcit Prestwick3_000692 Recital SAM002589960 ST069372 STL058639 Seropram Talam Talohexal Temperax UNII-0DHU5B8D6V Vodelax Zentius Zetalo [3H]Citalopram citalopram | |
| | 20 | | Minocycline | approved, investigational | Phase 4 | 173 | 10118-90-8 | 5281021 | (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE (4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 10118-90-8 13614-98-7 (mono-hydrochloride) 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide 4708-96-7 7-Dimethylamino-6-demethyl-6-deoxytetracycline AC1NQXWM Arestin BRN 3077644 Bio-0062 Borymycin C07225 C23H27N3O7 CHEBI:50694 CHEBI:529981 CHEMBL1434 CHEMBL259172 CID5281021 CL 59806 CRL-1605 & Minocycline D05045 Dynacin HMS2090D03 HSDB 3130 LMPK07000002 | LS-93850 Lactoferrin B & Minocycline Lactoferrin H & Minocycline MINO MIY Minociclina Minociclina [INN-Spanish] Minociclinum Minocin Minocin (Hydrochloride) Minocline Minocyclin Minocycline Minocycline (USAN/INN) Minocycline Hydrochloride Minocycline Monohydrochloride Minocycline [USAN:BAN:INN] Minocyclinum Minocyclinum [INN-Latin] NCGC00178854-01 NSC 141993 NSC141993 Solodyn UNII-FYY3R43WGO Vectrin (Hydrochloride) Ximino minociclinum minocycline nchembio.559-comp1 |
| | 21 | | Ornithine | approved, nutraceutical | Phase 4, Phase 2 | 63 | 70-26-8 | 6262 | (+)-S-Ornithine (S)-2,5-Diaminopentanoate (S)-2,5-Diaminopentanoic acid (S)-2,5-diaminovaleric acid (S)-Ornithine (S)-a,D-Diaminovalerate | (S)-a,D-Diaminovaleric acid (S)-alpha,delta-Diaminovaleric acid (S)-ornithine (S)-α,δ-diaminovaleric acid 5-Amino-L-Norvaline L-(-)-Ornithine L-Ornithine | |
| | 22 | | Pharmaceutical Solutions | | Phase 4, Phase 3, Phase 2, Phase 1 | 7004 | | | | 23 | | Gamma-Globulins | | Phase 4 | 22 | | | | 24 | | Anti-Infective Agents | | Phase 4, Phase 3, Phase 2 | 17220 | | | | 25 | | Analgesics | | Phase 4, Phase 3 | 9358 | | | | 26 | | Antiviral Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 8071 | | | | 27 | | lenograstim | | Phase 4, Phase 3, Phase 2 | 1134 | | | | 28 | | Antimetabolites | | Phase 4, Phase 3, Phase 2, Phase 1 | 9454 | | | | 29 | | Anti-Retroviral Agents | | Phase 4 | 2794 | | | | 30 | | Immunologic Factors | | Phase 4, Phase 3, Phase 2, Phase 1 | 18483 | | | | 31 | | Anesthetics | | Phase 4, Phase 1 | 7385 | | | | 32 | | Antifungal Agents | | Phase 4, Phase 3, Phase 2 | 3015 | | | | 33 | | Liver Extracts | | Phase 4, Phase 3, Phase 2, Phase 1 | 3572 | | | | 34 | | Nucleic Acid Synthesis Inhibitors | | Phase 4, Phase 3, Phase 2 | 3836 | | | | 35 | | Antioxidants | | Phase 4, Phase 3, Phase 1, Phase 2 | 2442 | | | | 36 | | Expectorants | | Phase 4, Phase 3, Phase 2 | 337 | | | | 37 | | N-monoacetylcystine | | Phase 4, Phase 3, Phase 2 | 293 | | | | 38 | | Contraceptives, Oral | | Phase 4 | 3734 | | | | 39 | | Calcineurin Inhibitors | | Phase 4, Phase 3, Phase 2, Phase 1 | 1223 | | | | 40 | | Respiratory System Agents | | Phase 4, Phase 3, Phase 2 | 3931 | | | | 41 | | Reverse Transcriptase Inhibitors | | Phase 4 | 1656 | | | | 42 | | Anti-Bacterial Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 9140 | | | | 43 | | Anticoagulants | | Phase 4, Phase 3 | 1760 | | | | 44 | | Central Nervous System Depressants | | Phase 4 | 10016 | | | | 45 | | Immunosuppressive Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 10422 | | | | 46 | | N-Methylaspartate | | Phase 4, Phase 2 | 98 | | | | 47 | | Calcium, Dietary | | Phase 4 | 4678 | | | | 48 | | Methylprednisolone acetate | | Phase 4, Phase 3, Phase 2, Phase 1 | 1082 | | | | 49 | | Methylprednisolone Hemisuccinate | | Phase 4, Phase 3, Phase 2, Phase 1 | 1082 | | | | 50 | | Neurotransmitter Agents | | Phase 4, Phase 2 | 14795 | | |
Interventional clinical trials: (show top 50)
(show all 229)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure | Completed | NCT01074645 | Phase 4 | | 2 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" | Completed | NCT01201720 | Phase 4 | | 3 | A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B | Completed | NCT00380614 | Phase 4 | | 4 | Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy | Completed | NCT01269112 | Phase 4 | | 5 | Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. | Completed | NCT01041755 | Phase 4 | | 6 | Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis | Completed | NCT00886925 | Phase 4 | | 7 | Steroids and/or Growth Hormone in Fulminant Hepatic Failure in the Pediatric Age Group | Recruiting | NCT02375867 | Phase 4 | | 8 | Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography | Recruiting | NCT02757170 | Phase 4 | | 9 | RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure | Recruiting | NCT02331745 | Phase 4 | | 10 | Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure | Recruiting | NCT01968395 | Phase 4 | | 11 | Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding | Recruiting | NCT02158182 | Phase 4 | | 12 | L-ornithine L-aspartate in Overt Hepatic Encephalopathy | Recruiting | NCT01722578 | Phase 4 | | 13 | Different Schemes of Magnesium Sulfate for Preeclampsia | Recruiting | NCT02396030 | Phase 4 | | 14 | Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection | Active, not recruiting | NCT00163657 | Phase 4 | | 15 | Minocycline Administration During Human Liver Transplantation | Not yet recruiting | NCT02712775 | Phase 4 | | 16 | Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit | Not yet recruiting | NCT00872027 | Phase 4 | | 17 | Study of N-Acetylcysteine in Acute Liver Failure (ALF) | Terminated | NCT00896025 | Phase 4 | | 18 | Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation | Terminated | NCT00656266 | Phase 4 | | 19 | A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. | Completed | NCT00248625 | Phase 3 | | 20 | Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen | Completed | NCT00004467 | Phase 3 | | 21 | Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure | Completed | NCT01383460 | Phase 3 | | 22 | The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure | Completed | NCT00224705 | Phase 3 | | 23 | Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure | Completed | NCT01471028 | Phase 3 | | 24 | CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment | Completed | NCT00604357 | Phase 3 | | 25 | Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients | Completed | NCT01150097 | Phase 3 | | 26 | Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids | Completed | NCT00149890 | Phase 3 | | 27 | Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients | Completed | NCT00622869 | Phase 3 | | 28 | A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients | Completed | NCT01625377 | Phase 3 | | 29 | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients | Completed | NCT00497796 | Phase 3 | | 30 | RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency | Completed | NCT00267189 | Phase 3 | | 31 | Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study) | Completed | NCT00883948 | Phase 3 | | 32 | Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant | Completed | NCT02118896 | Phase 3 | | 33 | Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD | Recruiting | NCT02612428 | Phase 3 | | 34 | Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection | Recruiting | NCT02710266 | Phase 3 | | 35 | Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study | Recruiting | NCT02451033 | Phase 2, Phase 3 | | 36 | Preoperative Glucocorticoid Use in Major Hepatectomy | Recruiting | NCT01997658 | Phase 2, Phase 3 | | 37 | Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage | Recruiting | NCT00553423 | Phase 3 | | 38 | Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy | Recruiting | NCT02464124 | Phase 2, Phase 3 | | 39 | Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants | Recruiting | NCT01888432 | Phase 3 | | 40 | REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy | Recruiting | NCT02115113 | Phase 3 | | 41 | Diuretic Versus Placebo in Pulmonary Embolism | Recruiting | NCT02268903 | Phase 3 | | 42 | Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia | Recruiting | NCT02348788 | Phase 3 | | 43 | The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury | Recruiting | NCT00987688 | Phase 3 | | 44 | Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. | Active, not recruiting | NCT01598987 | Phase 3 | | 45 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | Active, not recruiting | NCT00354835 | Phase 3 | | 46 | Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD | Not yet recruiting | NCT02411084 | Phase 3 | | 47 | Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure | Terminated | NCT01829347 | Phase 3 | | 48 | Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation | Terminated | NCT00151632 | Phase 3 | | 49 | Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study) | Terminated | NCT00609180 | Phase 3 | | 50 | Alefacept for Prevention of Graft Versus Host Disease (GVHD) | Terminated | NCT00361413 | Phase 3 |
Cell-based therapeutics:Data from LifeMap, the Embryonic Development and Stem Cells Database Stem-cell-based therapeutic approaches for Acute Liver Failure: Embryonic/Adult Cultured Cells Related to Acute Liver Failure:  | Hepatocytes, PMIDs: 15239608, 12777539, 9580649, 22789058, 22167636 | | Hepatocytes | | Liver cells, PMIDs: 22532025, 19295306, 19796496, 16454359, 17060866 |
|
